Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 14 2 2020 04 07 123 126 Flávia Russo 1) Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil 2) Bio Sana`s serviços Médicos, São Paulo, Brazil Maria Cristina Macedo 1) Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil 2) Bio Sana`s serviços Médicos, São Paulo, Brazil Pedro Fernandes 1) Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil 2) Bio Sana`s serviços Médicos, São Paulo, Brazil Larissa Okada 1) Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil 2) Bio Sana`s serviços Médicos, São Paulo, Brazil Lucas da Silva Faculdade de Ciências Médicas Santa Casa de São Paulo, São Paulo, Brazil Camila Simões 1) Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil 2) Bio Sana`s serviços Médicos, São Paulo, Brazil Jamilla Cavalcante 1) Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil 2) Bio Sana`s serviços Médicos, São Paulo, Brazil Aline Simões 1) Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil 2) Bio Sana`s serviços Médicos, São Paulo, Brazil Manuella Almeida 1) Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil 2) Bio Sana`s serviços Médicos, São Paulo, Brazil Maricy Lopes 1) Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil 2) Bio Sana`s serviços Médicos, São Paulo, Brazil Roberto da Silva 1) Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil 2) Bio Sana`s serviços Médicos, São Paulo, Brazil 2019 07 27 2019 11 09 Acute Lymphoblastic Leukemia is a very aggressive malignant disorder of lymphoid cells in adults, with recurrence (30 to 60% of the cases) after the initial treatment. Until this moment, there is no gold standard therapy for the treatment of adult patients with acute relapsed/refractory lymphoblastic leukemia. In this case report, we describe two cases of relapsed leukemia: one of lymphocytic leukemia B and one of trilineage leukemia, which presented a satisfactory response to treatment with Bortezomib associated with Vincristine, Dexamethasone, and Bendamustine. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1161 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1161/821